Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Faricimab for choroidal neovascularization secondary to pathologic myopia is active but not recruiting (NCT06176352).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization Secondary to Pathologic Myopia

Drugs mentioned

• VABYSMO (faricimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Status: ACTIVE_NOT_RECRUITING